Last reviewed · How we verify
NCT06256185
Machine Learning to Predict Lymph Node Metastasis in T1 Esophageal Squamous Cell Carcinoma
NA trial testing esophagectomy in Lymph Node Metastasis in 1,267 participants. Completed in 15 July 2023.
15 December 2019
Quick facts
| Lead sponsor | Shanghai Zhongshan Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 1,267 |
| Start date | 15 January 2010 |
| Primary completion | 15 December 2019 |
| Estimated completion | 15 July 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- esophagectomy
Conditions studied
- Lymph Node Metastasis — all drugs for Lymph Node Metastasis →
Sponsor
Shanghai Zhongshan Hospital
Who can join
Eligibility, any sex, with Lymph Node Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Existing models do poorly when it comes to quantifying the risk of Lymph node metastases (LNM). This study generated elastic net regression (ELR), random forest (RF), extreme gradient boosting (XGB), and a combined (ensemble) model of these for LNM in patients with T1 esophageal squamous cell carcinoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Machine learning to predict lymph node metastasis in T1 esophageal squamous cell carcinoma: a multicenter study.
Huang X, Wang Q, Xu W, Liu F, et al · · 2024 · cited 7× · PMID 38905510 · DOI 10.1097/js9.0000000000001694
Verify or expand the search:
- PubMed search for NCT06256185
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of esophagectomy
Trials testing the same drug.
- NCT07312526 — Shanghai Clinical Cohort - Esophageal Cancer · completed
- NCT05812235 — Bone Microstructure by Using HR-pQCT After Esophagectomy · not yet recruiting
- NCT05357846 — PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) · Phase 3 · recruiting
- NCT04135664 — Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma · Phase 3 · recruiting
- NCT03094351 — Robot-assisted Esophagectomy Versus Conventional Thoracoscopic Esophagectomy · Phase 3 · unknown
Other recruiting trials for Lymph Node Metastasis
Currently open trials in the same condition.
- NCT06829147 — A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC) · recruiting
- NCT06623266 — Neck Observation or Elective Neck Dissection in CT1N0M0 OSCC · NA · recruiting
- NCT06621823 — Image-guided Ultrasound Robotic Intraoperative Evaluation of Lymph-nodes Status in Gynecological Malignancies · NA · recruiting
- NCT06264167 — NODE (groiN ultrasOunD cancEr) · NA · recruiting
- NCT07050576 — Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma · recruiting
Other Shanghai Zhongshan Hospital trials
Trials by the same sponsor.
- NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
- NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
- NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
- NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
- NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06256185 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
- Last refreshed: 13 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06256185.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing